Absci Q2 revenue falls and misses analyst expectations
Absci Q2 revenue falls and misses analyst expectations
Overview
US biopharma firm's Q2 revenue fell and missed analyst expectations
Net loss widened as R&D expenses rose due to advancing internal programs
Company completed $100 mln offering, including $40 mln investment from Eli Lilly
Outlook
Absci expects interim proof-of-concept data for ABS-201 in pattern hair loss in H2 2026
Company plans full proof-of-concept data for ABS-201 in pattern hair loss in early 2027
Absci expects to initiate Phase 2 trial for endometriosis in Q4 2026, with data in H2 2027
Result Drivers
R&D SPENDING - Co said higher research and development expenses were driven by advancement of internal programs, including clinical development of ABS-201
POSITIVE TRIAL DATA - Co reported favorable safety and tolerability in interim Phase 1 data for ABS-201, supporting potential for convenient dosing
CASH INFUSION - Co completed $100 mln offering, including $40 mln strategic investment from Eli Lilly, extending funding into H2 2028
Company press release: ID:nGNX9vLP72
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $318,000 | $1.17 mln (7 Analysts) |
Q2 Net Loss |
| $33.21 mln |
|
Q2 Loss Per Basic Share |
| $0.21 |
|
Q2 Operating Expenses |
| $34.48 mln |
|
Q2 Operating Income |
| -$34.16 mln |
|
Q2 Pretax Loss |
| $33.17 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Absci Corp is $14.00, about 55.4% above its August 10 closing price of $9.01
Reuters Recommended Reads
Aug 11 - LB Pharmaceuticals Q2 net loss widens on higher R&D costs
Aug 10 - Eli Lilly's weight-loss pill secures first European nod in Britain
Aug 10 - Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave